<?xml version="1.0" encoding="UTF-8"?>
<p id="p0005">In light of the Coronavirus Disease 2019 (COVID-19) pandemic, world leaders and the media have propelled various treatment modalities that have not been approved by the US Food and Drug Administration (FDA) to prevent or cure acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Such treatments include nucleotide analogs (remdesivir), anti-malarial drugs (chloroquine and hydroxychloroquine), protease inhibitors (lopinavir/ritonavir), interferon-
 <italic>Î²</italic>, nonsteroidal anti-inflammatory drugs (NSAIDs), and renin angiotensin aldosterone system (RAAS) antagonists [
 <xref rid="bb0005" ref-type="bibr">[1]</xref>, 
 <xref rid="bb0010" ref-type="bibr">[2]</xref>, 
 <xref rid="bb0015" ref-type="bibr">[3]</xref>]. The unprecedented circumstances surrounding this pandemic does not discard the responsibility of respecting medical ethics, ensuring that medical information is accurate, and the published data meets expected scientific standards. Clinical trials testing the efficacy of single and combination treatments are needed to make clear recommendations for treating COVID-19. To date, there are no evidence-based treatments for COVID-19.
</p>
